The liver damage can develop for years without notice, while accurate diagnosis often requires specialized examinations. But a new experimental test that uses artificial intelligence to analyze DNA in the blood can change the way this organ is exposed. The results presented in the United States have shown comparable accuracy with one of the most advanced methods of medical imaging.
Scientists have introduced a new method of valuing chronic liver diseases that can facilitate diagnostic patients without the need for complex testing.
According to Reuters agency, the results were presented on November 5th at the annual conference of the American Association for the Study of Mercy Diseases, in Denver, U.S.A.
Experimental technology, called LiquidTransformer, has been developed by the biotechnology company Hepta and analyzes DNA fragments that circulate into the blood.
Through artificial intelligence, the system aims to identify biological changes that indicate whether the liver is affected by inflammation and fibronation, the process in which normal tissues are gradually replaced by internal tissue.
What has attracted the attention of researchers is that the test has shown comparable performance with magnetic resonar elastography, a very precise method, but not easily available in any health institution.
In an independent group of 229 patients with a diagnosis confirmed through biopsy, the method showed promising results in identifying the liver fibrosis that may require treatment.
According to data presented, the test has surpassed the performance of several other noninvasive methods in the comparisons developed during the study.
Why is this discovery important?
One of the diseases intended to identify this technology is KAS, a more serious form of obese liver disease associated with inflammation and progressive organ damage.
If not identified and treated in time, the disease can progress toward cirrhosis and serious complications.
The possible advantage of the new method is that information about the extent of the damage can be obtained from a blood sample without the use of advanced devices or the taking of tissues for biopsy always being used.
Researchers have also reported that technology can help distinguish certain forms of liver disease, including those related to metabolic disorders and alcohol consumption.
Can patients do this analysis now?
Despite promising results, the test is not yet a routine analysis approved for widespread clinical use.
Technology continues to develop, and further assessments are needed before its use is determined in daily medical practice.
This means that patients should not replace existing tests, recommended examinations, or medical consultation by relying solely on the results of this study.
However, if the results are confirmed in further studies, a blood sample can become a much more powerful tool for early liver damage detection and assessment.
The signal where the truth speaks before the news!
Source Layer: Signal